カルバペネム系抗生物質市場レポート：2031年までの動向、予測、競合分析

カルバペネム系抗生物質の世界市場の将来は、病院薬局、小売薬局、オンライン薬局の各市場における機会で有望視されています。世界のカルバペネム系抗生物質市場は、2025年から2031年にかけてCAGR 5.4％で成長すると予想されます。この市場の主な促進要因は、細菌感染率の上昇と手術件数の増加です。

• Lucintel社の予測では、タイプ別ではメロペネムが予測期間中に最も高い成長を遂げる見込みです。
• 流通チャネル別では、病院薬局が最も高い成長が見込まれます。
• 地域別では、医療インフラが確立されている北米が予測期間中に最も高い成長が見込まれます。

カルバペネム系抗生物質市場の戦略的成長機会

カルバペネム系抗生物質市場は、世界のヘルスケア情勢が抗生物質耐性感染症の脅威の高まりに対処し続けていることから、成長の態勢が整っています。この懸念の高まりは、製薬業界の利害関係者にさまざまな戦略的機会をもたらします。研究の進展を活用し、規制の枠組みを改善し、協力関係を促進することで、企業はこの重要な市場を活用することができます。このような機会を特定し追求することは、耐性パターンが進化する中で革新的な治療法を開発し、患者の転帰を改善するために不可欠です。

• 新規抗生物質の開発：耐性菌が増加する中、新規カルバペネム系抗生物質の開発が急務となっています。製薬会社は、新規化合物の創出や既存化合物の改良に研究開発の労力を集中させることができ、アンメット・メディカル・ニーズを展開し、市場でのプレゼンスを拡大することができます。
• 新興市場への進出：新興市場でヘルスケアのインフラが整備されるにつれ、効果的な抗生物質療法に対する需要が高まっています。企業はこうした地域での事業機会を模索し、現地でのパートナーシップを確立して販売チャネルを拡大することで、多剤耐性感染症の蔓延の増加に対処することができます。
• 併用療法への投資：カルバペネムを他の抗生物質や補助剤との併用療法への戦略的投資は、複雑な感染症に対する新たな治療選択肢を生み出すことができます。このアプローチは有効性を高めるだけでなく、耐性菌の発展を遅らせることにも役立ち、市場での競争優位性をもたらします。
• 個別化医療への注力：個別化医療へのシフトは、カルバペネム市場に大きな成長機会をもたらします。遺伝子および微生物学的プロファイルに基づく標的治療の開発は、治療効果と患者の転帰を改善し、企業を革新的な抗生物質ソリューションのリーダーとして位置づけることができます。
• 抗菌薬管理プログラムの強化：抗菌薬スチュワードシップを推進するためにヘルスケア機関と協力することで、カルバペネム系抗生物質の責任ある使用を強化することができます。Global health initiatives と連携することで、企業は患者の転帰を改善し、耐性菌を減らし、持続可能な慣行がますます重視される市場においてブランドの評判を高めることができます。

カルバペネム系抗生物質市場は、世界が抗生物質耐性の課題に立ち向かう中で、いくつかの戦略的成長機会を提示しています。新規抗生物質の開発に注力し、新興国市場に進出し、併用療法に投資し、個別化医療を受け入れ、抗菌薬スチュワードシップ・プログラムを支援することで、企業は成功に向けて自らを位置づけることができます。このような機会を捉えることは、治療の選択肢を増やし、耐性感染症との闘いにおける健康転帰を改善するために極めて重要です。

カルバペネム系抗生物質市場促進要因・課題

カルバペネム系抗生物質市場は、抗生物質耐性という世界の課題に対処する緊急の必要性に後押しされ、急速に発展しています。多剤耐性菌による感染症が増加する中、効果的なカルバペネム系治療薬に対する需要はかつてないほど高まっています。しかし、市場は成長と技術革新を妨げる重大な課題にも直面しています。これらの促進要因と課題を理解することは、この複雑な状況を乗り切り、耐性感染との闘いにおける影響力を強化するための戦略を策定しようとする利害関係者にとって不可欠です。

カルバペネム系抗生物質市場を牽引している要因は以下の通りです：

• 抗生物質耐性の増加：抗生物質耐性の増加は、カルバペネム系抗生物質市場の主要な促進要因です。細菌が進化し、既存の治療法に対して耐性を持つようになるにつれ、医療従事者は最後の砦としてカルバペネム系抗生物質に頼るようになっており、こうした深刻な感染症に対処するための新しく効果的な選択肢に対する需要が高まっています。
• 研究開発投資の拡大：新規カルバペネム系抗生物質の研究開発に注力する製薬企業の投資が急増しています。この動向は、抗生物質耐性の危機に対処し、技術革新を促し、より多様で効果的な治療法のパイプラインを構築することを目的とした公衆衛生上の取り組みによって後押しされています。
• 規制当局によるサポートの強化：規制当局は、新しい抗生物質、特に耐性感染症を対象とした抗生物質の承認を優先するようになってきています。カルバペネム系薬剤の承認プロセスを迅速化するイニシアチブは、メーカーが製品をより迅速に市場に投入できる環境を提供し、同分野の成長を促進します。
• ヘルスケアに対する意識の高まり：抗生物質耐性に対する医療従事者や患者の意識の高まりが、効果的な治療に対する需要を促進しています。この問題に対する理解を促進することを目的とした教育的イニシアティブやキャンペーンは、カルバペネム系抗生物質の開発と適切な利用の重要性により焦点を当てることに貢献しています。
• 新興市場での拡大：新興国市場では、ヘルスケアシステムの発展に伴い、効果的な抗生物質治療に対する需要が高まっています。ヘルスケアへのアクセスが改善し、感染症の負担が増加していることから、カルバペネム系抗生物質市場の成長機会は大きく、企業はこれらの地域での事業展開と製品提供を拡大しています。

カルバペネム系抗生物質市場における課題は以下のとおりです：

• 高い開発コスト：カルバペネム市場における重要な課題の1つは、新規抗生物質の開発に伴うコストの高さです。抗生物質開発の複雑な性質と厳しい規制要件が相まって、投資が抑制され、革新的な治療法の市場導入が遅れる可能性があります。

市場独占期間の短さ：新規抗生物質の独占販売期間が限られていることは、製薬企業にとって課題です。特許の有効期限が比較的早く切れることや、ジェネリック医薬品の急速な台頭により、企業は研究開発への投資回収に苦戦する可能性があり、長期的な収益性や技術革新のインセンティブに影響を与えます。

• 高まる規制当局の監視：抗生物質の使用や承認に関する規制当局の監視が強化されることは、メーカーにとって課題となります。企業は厳しいコンプライアンス要件をクリアし、製品の有効性と安全性を実証しなければならないため、開発プロセスが遅れ、市場開発の妨げとなる可能性があります。

カルバペネム系抗生物質市場は、抗生物質耐性の向上、研究開発投資の増加、規制当局の支援強化、ヘルスケア意識の高まり、新興市場での拡大といった重要な要因によって牽引されています。しかし、開発コストの高さ、市場独占期間の短さ、規制当局による監視の強化といった課題も依然として残っています。これらの促進要因と課題に対処することは、抗生物質耐性感染症との継続的な闘いにおいて革新的で効果的な解決策を提供することを目指す利害関係者にとって極めて重要です。

目次

第1章 エグゼクティブサマリー

第2章 世界のカルバペネム系抗生物質市場：市場力学

• イントロダクション、背景、分類
• サプライチェーン
• 業界の促進要因と課題

第3章 2019年から2031年までの市場動向と予測分析

• マクロ経済動向（2019-2024年）と予測（2025-2031年）
• 世界のカルバペネム系抗生物質市場の動向（2019年～2024年）と予測（2025年～2031年）
• タイプ別：カルバペネム系抗生物質の世界市場
  • メロペネム
  • イミペネム
  • ドリペネム
  • テビペネム
  • その他
• 適応症別：カルバペネム系抗生物質の世界市場
  • 腹腔内感染症
  • 尿路感染症
  • 肺炎
  • 細菌性髄膜炎
  • 皮膚および皮膚構造の感染症
  • 急性骨盤感染症
  • その他
• 流通チャネル別：カルバペネム系抗生物質の世界市場
  • 病院薬局
  • 小売薬局
  • オンライン薬局

第4章 2019年から2031年までの地域別市場動向と予測分析

• 地域別：カルバペネム系抗生物質の世界市場
• 北米のカルバペネム系抗生物質市場
• 欧州のカルバペネム系抗生物質市場
• アジア太平洋地域のカルバペネム系抗生物質市場
• その他地域のカルバペネム系抗生物質市場

第5章 競合分析

• 製品ポートフォリオ分析
• 運用統合
• ポーターのファイブフォース分析

第6章 成長機会と戦略分析

• 成長機会分析
  • タイプ別：カルバペネム系抗生物質の世界市場の成長機会
  • 適応症別：世界のカルバペネム系抗生物質市場の成長機会
  • 流通チャネル別：カルバペネム系抗生物質市場の成長機会
  • 地域別：カルバペネム系抗生物質市場の成長機会
• 世界のカルバペネム系抗生物質市場の新たな動向
• 戦略分析
  • 新製品開発
  • 世界のカルバペネム系抗生物質市場の生産能力拡大
  • 世界のカルバペネム系抗生物質市場における合併、買収、合弁事業
  • 認証とライセンシング

第7章 主要企業の企業プロファイル

• Pfizer
• Merck
• Saint-Gobain
• Fresenius Kabi
• GlaxoSmithKline
• Eli Lilly and Company
• Teva Pharmaceutical Industries
• AstraZeneca
• Meiji Holdings
• Sandoz International

The future of the global carbapenem-based antibiotic market looks promising with opportunities in the hospital pharmacy, retail pharmacy, and online pharmacy markets. The global carbapenem-based antibiotic market is expected to grow with a CAGR of 5.4% from 2025 to 2031. The major drivers for this market are the rising rates of bacterial infections and the increasing quantity of surgical procedures carried out.

• Lucintel forecasts that, within the type category, meropenem is expected to witness the highest growth over the forecast period.
• Within the distribution channel category, hospital pharmacy is expected to witness the highest growth.
• In terms of regions, North America is expected to witness the highest growth over the forecast period due to the presence of well-established healthcare infrastructure in this region.

Gain valuable insights for your business decisions with our comprehensive 150+ page report.

Emerging Trends in the Carbapenem-Based Antibiotic Market

The carbapenem-based antibiotic market is evolving rapidly as the global healthcare landscape confronts the urgent challenge of antibiotic resistance. With rising cases of multidrug-resistant infections, there is a renewed focus on developing effective therapies. Innovations in research, changes in regulatory frameworks, and increased investment from both public and private sectors are shaping the market. As we delve into this dynamic environment, several emerging trends are reshaping the landscape for carbapenem antibiotics.

• Increased Research and Development: Pharmaceutical companies are investing heavily in R&D to discover novel carbapenem antibiotics and enhance existing formulations. This trend is driven by the pressing need to address resistant pathogens, leading to collaborations between academia and industry, ultimately fostering innovation and accelerating drug development timelines.
• Regulatory Support and Streamlined Approvals: Regulatory agencies are responding to the antibiotic crisis by expediting approval processes for new carbapenem drugs. Initiatives like the FDA's Qualified Infectious Disease Product (QIDP) designation are designed to incentivize the development of critically needed antibiotics, allowing for faster market entry and enhanced financial support for manufacturers.
• Focus on Combination Therapies: There is a growing trend toward developing combination therapies that include carbapenems alongside other antibiotics or adjuvants. This approach aims to enhance efficacy against resistant strains, reduce the likelihood of resistance development, and provide clinicians with more effective treatment options for complex infections.
• Rise of Personalized Medicine: The movement toward personalized medicine is influencing the carbapenem market as genomic technologies advance. Tailoring antibiotic treatments based on individual patient profiles and microbial resistance patterns promises to improve treatment outcomes and minimize side effects, making it a key focus for future developments.
• Expansion in Emerging Markets: Emerging markets, particularly in Asia and Africa, are witnessing increased demand for carbapenem antibiotics. Economic growth and rising healthcare access are contributing to this trend, prompting pharmaceutical companies to expand their portfolios and distribution networks to meet the needs of these rapidly evolving markets.

The carbapenem-based antibiotic market is poised for significant transformation as it adapts to the challenges posed by antibiotic resistance. Emerging trends such as increased R&D, regulatory support, combination therapies, personalized medicine, and market expansion highlight the ongoing commitment to developing effective solutions. These advancements are essential in the ultimate fight against resistant infections, ensuring better health outcomes for patients globally.

Recent Developments in the Carbapenem-Based Antibiotic Market

The carbapenem-based antibiotic market is rapidly evolving in response to the global challenge of antibiotic resistance. With rising infection rates caused by multidrug-resistant pathogens, the demand for effective carbapenem therapies is increasing. Recent advancements in research, regulatory frameworks, and collaborative efforts among stakeholders are reshaping this critical market segment. As healthcare systems work to combat the threat of resistant infections, several noteworthy developments have emerged, highlighting the proactive measures being taken to enhance the availability and efficacy of carbapenem antibiotics.

• New Drug Approvals: Recent months have seen several new carbapenem antibiotics receiving regulatory approval, aimed specifically at treating multidrug-resistant infections. These approvals are crucial as they expand the therapeutic arsenal available to clinicians, offering hope for better patient outcomes and demonstrating a commitment to addressing the antibiotic resistance crisis.
• Enhanced Formulations: Pharmaceutical companies are developing improved formulations of existing carbapenem antibiotics to enhance stability and bioavailability. These advancements aim to optimize dosing regimens, reduce side effects, and increase the overall efficacy of treatments, thereby providing healthcare providers with more effective options for managing severe infections.
• Focus on Combination Therapies: There is a growing emphasis on combination therapies involving carbapenems alongside other antibiotics or adjuncts. This approach aims to enhance the overall effectiveness of treatment regimens against resistant bacterial strains, reduce the risk of resistance development, and provide more comprehensive care for patients facing complex infections.
• Increased Investment in R&D: Significant investment in research and development is being observed as pharmaceutical companies and research institutions collaborate to innovate new carbapenem antibiotics. This trend is critical for addressing the urgent need for novel therapies, reflecting a proactive approach to tackling the evolving landscape of antibiotic resistance.
• Global Partnerships and Collaborations: There is a notable increase in global partnerships between pharmaceutical companies, research institutions, and governmental agencies. These collaborations focus on sharing knowledge, resources, and technologies to accelerate the development and distribution of effective carbapenem antibiotics, particularly in regions most affected by antibiotic resistance.

The carbapenem-based antibiotic market is undergoing significant changes driven by the pressing need to combat antibiotic resistance. Recent developments, including new drug approvals, enhanced formulations, combination therapies, increased R&D investments, and global partnerships, showcase a proactive response from the healthcare community. These advancements are vital in ensuring the availability of effective treatments for patients and addressing the ongoing challenges posed by resistant infections.

Strategic Growth Opportunities for Carbapenem-Based Antibiotic Market

The carbapenem-based antibiotic market is poised for growth as the global healthcare landscape continues to grapple with the rising threat of antibiotic-resistant infections. This growing concern presents a range of strategic opportunities for stakeholders in the pharmaceutical industry. By leveraging advancements in research, improving regulatory frameworks, and fostering collaborations, companies can position themselves to capitalize on this critical market. Identifying and pursuing these opportunities will be essential for developing innovative therapies and improving patient outcomes in the face of evolving resistance patterns.

• Development of Novel Antibiotics: There is a pressing need for the development of novel carbapenem antibiotics to combat increasingly resistant bacterial strains. Pharmaceutical companies can focus their R&D efforts on creating new compounds or improving existing ones, tapping into unmet medical needs and expanding their market presence.
• Expansion into Emerging Markets: As healthcare infrastructure improves in emerging markets, there is an increasing demand for effective antibiotic therapies. Companies can explore opportunities in these regions, establishing local partnerships and expanding distribution channels to address the rising prevalence of multidrug-resistant infections.
• Investment in Combination Therapies: Strategic investment in combination therapies that pair carbapenems with other antibiotics or adjuvants can create new treatment options for complex infections. This approach not only enhances efficacy but also helps in delaying the development of resistance, presenting a competitive advantage in the market.
• Focus on Personalized Medicine: The shift toward personalized medicine offers a significant growth opportunity for the carbapenem market. Developing targeted therapies based on genetic and microbiological profiles can improve treatment efficacy and patient outcomes, positioning companies as leaders in innovative antibiotic solutions.
• Strengthening Antimicrobial Stewardship Programs: Collaborating with healthcare institutions to promote antimicrobial stewardship can enhance the responsible use of carbapenem antibiotics. By aligning with global health initiatives, companies can improve patient outcomes, reduce resistance, and strengthen their brand reputation in a market increasingly focused on sustainable practices.

The carbapenem-based antibiotic market presents several strategic growth opportunities as the world confronts the challenges of antibiotic resistance. By focusing on the development of novel antibiotics, expanding into emerging markets, investing in combination therapies, embracing personalized medicine, and supporting antimicrobial stewardship programs, companies can position themselves for success. Seizing these opportunities will be crucial for enhancing treatment options and improving health outcomes in the fight against resistant infections.

Carbapenem-Based Antibiotic Market Driver and Challenges

The carbapenem-based antibiotic market is rapidly evolving, driven by the urgent need to address the global challenge of antibiotic resistance. As infections caused by multidrug-resistant bacteria rise, the demand for effective carbapenem therapies is more critical than ever. However, the market also faces significant challenges that could hinder growth and innovation. Understanding these drivers and challenges is essential for stakeholders looking to navigate this complex landscape and develop strategies to enhance their impact in the fight against resistant infections.

The factors responsible for driving the carbapenem-based antibiotic market include:

• Increasing Antibiotic Resistance: The escalating prevalence of antibiotic-resistant infections is a primary driver for the carbapenem market. As bacteria evolve and become resistant to existing treatments, healthcare providers are increasingly relying on carbapenems as a last line of defense, driving demand for new and effective options to combat these serious infections.
• Growing Investment in R&D: There is a noticeable surge in investment from pharmaceutical companies focusing on research and development of new carbapenem antibiotics. This trend is fueled by public health initiatives aimed at addressing the antibiotic resistance crisis, encouraging innovation, and creating a more diverse pipeline of effective treatments.
• Enhanced Regulatory Support: Regulatory agencies are increasingly prioritizing the approval of new antibiotics, particularly those targeting resistant infections. Initiatives that expedite the approval process for carbapenem drugs provide manufacturers with a conducive environment to bring their products to market more quickly, fostering growth in the sector.
• Rising Healthcare Awareness: Increased awareness among healthcare providers and patients about antibiotic resistance is driving demand for effective treatments. Educational initiatives and campaigns aimed at promoting understanding of this issue contribute to a greater focus on the importance of developing and utilizing carbapenem antibiotics appropriately.
• Expansion in Emerging Markets: Emerging markets are witnessing a rise in demand for effective antibiotic therapies as healthcare systems develop. Improved access to healthcare and the rising burden of infections present significant opportunities for growth in the carbapenem market, encouraging companies to expand their reach and product offerings in these regions.

Challenges in the carbapenem-based antibiotic market are:

• High Development Costs: One of the significant challenges in the carbapenem market is the high cost associated with developing new antibiotics. The complex nature of antibiotic development, coupled with stringent regulatory requirements, can deter investment and slow the introduction of innovative therapies to the market.

Short Market Exclusivity: The limited exclusivity period for new antibiotics poses a challenge for pharmaceutical companies. With patents expiring relatively quickly and the rapid emergence of generics, companies may struggle to recoup their investment in research and development, impacting long-term profitability and innovation incentives.

• Growing Regulatory Scrutiny: Increasing scrutiny from regulatory bodies regarding antibiotic usage and approval can present challenges for manufacturers. Companies must navigate stringent compliance requirements and demonstrate the effectiveness and safety of their products, which can slow down the development process and hinder market entry.

The carbapenem-based antibiotic market is driven by significant factors such as rising antibiotic resistance, increased investment in R&D, enhanced regulatory support, growing healthcare awareness, and expansion in emerging markets. However, challenges including high development costs, short market exclusivity, and growing regulatory scrutiny remain prevalent. Addressing these drivers and challenges will be crucial for stakeholders aiming to innovate and provide effective solutions in the ongoing battle against antibiotic-resistant infections.

List of Carbapenem-Based Antibiotic Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. Through these strategies carbapenem-based antibiotic companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the carbapenem-based antibiotic companies profiled in this report include-

• Pfizer
• Merck
• Saint-Gobain
• Fresenius Kabi
• GlaxoSmithKline
• Eli Lilly and Company
• Teva Pharmaceutical Industries
• AstraZeneca
• Meiji Holdings
• Sandoz International

Carbapenem-Based Antibiotic by Segment

The study includes a forecast for the global carbapenem-based antibiotic market by type, indication, distribution channel, and region.

Carbapenem-Based Antibiotic Market by Type [Analysis by Value from 2019 to 2031]:

• Meropenem
• Imipenem
• Doripenem
• Tebipenem
• Others

Carbapenem-Based Antibiotic Market by Indication [Analysis by Value from 2019 to 2031]:

• Intra-Abdominal Infections
• Urinary Tract Infections
• Pneumonia
• Bacterial Meningitis
• Skin & Skin Structure Infections
• Acute Pelvic Infections
• Others

Carbapenem-Based Antibiotic Market by Distribution Channel [Analysis by Value from 2019 to 2031]:

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

Carbapenem-Based Antibiotic Market by Region [Analysis by Value from 2019 to 2031]:

• North America
• Europe
• Asia Pacific
• The Rest of the World

Country Wise Outlook for the Carbapenem-Based Antibiotic Market

The carbapenem-based antibiotic market is experiencing significant transformations due to rising antibiotic resistance, increased regulatory scrutiny, and the need for innovative therapies. As healthcare systems grapple with multidrug-resistant infections, countries like the United States, China, Germany, India, and Japan are focusing on enhancing their antibiotic development pipelines and improving access to effective treatments. Recent advancements include novel formulations, regulatory approvals, and strategic collaborations aimed at combating the growing threat of resistant pathogens.

• United States: The U.S. has seen a surge in research and development for new carbapenem formulations, with several companies receiving FDA approvals for innovative drugs that target resistant infections. Increased funding for antibiotic development and initiatives like the PASTEUR Act aims to incentivize manufacturers, fostering a more robust market landscape.
• China: China is witnessing rapid growth in its carbapenem market, driven by escalating rates of antibiotic resistance. The government is prioritizing antibiotic stewardship programs and investing in local pharmaceutical companies to develop novel carbapenem agents, leading to a rise in production capacity and improved regulatory frameworks.
• Germany: Germany is focusing on enhancing its antimicrobial stewardship programs to combat resistance. Recent collaborations between pharmaceutical firms and research institutions have led to the development of new carbapenem products. Regulatory bodies are streamlining approval processes, making it easier to bring innovative antibiotics to market.
• India: The Indian market is seeing significant advancements in the production of generic carbapenem antibiotics, driven by high demand due to resistant infections. Initiatives aimed at improving manufacturing standards and regulatory compliance are enhancing product quality, while government programs are promoting research into novel antibiotic solutions.
• Japan: Japan is actively addressing the challenge of antibiotic resistance through increased investment in research and development. Recent approvals for new carbapenem antibiotics are coupled with a push for international collaboration in drug development. The government is also emphasizing the importance of antibiotic stewardship to reduce overuse and misuse.

Features of the Global Carbapenem-Based Antibiotic Market

Market Size Estimates: Carbapenem-based antibiotic market size estimation in terms of value ($B).

Trend and Forecast Analysis: Market trends (2019 to 2024) and forecast (2025 to 2031) by various segments and regions.

Segmentation Analysis: Carbapenem-based antibiotic market size by type, indication, distribution channel, and region in terms of value ($B).

Regional Analysis: Carbapenem-based antibiotic market breakdown by North America, Europe, Asia Pacific, and Rest of the World.

Growth Opportunities: Analysis of growth opportunities in different type, indication, distribution channel, and regions for the carbapenem-based antibiotic market.

Strategic Analysis: This includes M&A, new product development, and competitive landscape of the carbapenem-based antibiotic market.

Analysis of competitive intensity of the industry based on Porter's Five Forces model.

If you are looking to expand your business in this market or adjacent markets, then contact us. We have done hundreds of strategic consulting projects in market entry, opportunity screening, due diligence, supply chain analysis, M & A, and more.

This report answers following 11 key questions:

• Q.1. What are some of the most promising, high-growth opportunities for the carbapenem-based antibiotic market by type (meropenem, imipenem, doripenem, tebipenem, and others), indication (intra-abdominal infections, urinary tract infections, pneumonia, bacterial meningitis, skin & skin structure infections, acute pelvic infections, and others), distribution channel (hospital pharmacies, retail pharmacies, and online pharmacies), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
• Q.2. Which segments will grow at a faster pace and why?
• Q.3. Which region will grow at a faster pace and why?
• Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
• Q.5. What are the business risks and competitive threats in this market?
• Q.6. What are the emerging trends in this market and the reasons behind them?
• Q.7. What are some of the changing demands of customers in the market?
• Q.8. What are the new developments in the market? Which companies are leading these developments?
• Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
• Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
• Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?

Table of Contents

1. Executive Summary

2. Global Carbapenem-Based Antibiotic Market : Market Dynamics

• 2.1: Introduction, Background, and Classifications
• 2.2: Supply Chain
• 2.3: Industry Drivers and Challenges

3. Market Trends and Forecast Analysis from 2019 to 2031

• 3.1. Macroeconomic Trends (2019-2024) and Forecast (2025-2031)
• 3.2. Global Carbapenem-Based Antibiotic Market Trends (2019-2024) and Forecast (2025-2031)
• 3.3: Global Carbapenem-Based Antibiotic Market by Type
  • 3.3.1: Meropenem
  • 3.3.2: Imipenem
  • 3.3.3: Doripenem
  • 3.3.4: Tebipenem
  • 3.3.5: Others
• 3.4: Global Carbapenem-Based Antibiotic Market by Indication
  • 3.4.1: Intra-Abdominal Infections
  • 3.4.2: Urinary Tract Infections
  • 3.4.3: Pneumonia
  • 3.4.4: Bacterial Meningitis
  • 3.4.5: Skin & Skin Structure Infections
  • 3.4.6: Acute Pelvic Infections
  • 3.4.7: Others
• 3.5: Global Carbapenem-Based Antibiotic Market by Distribution Channel
  • 3.5.1: Hospital Pharmacies
  • 3.5.2: Retail Pharmacies
  • 3.5.3: Online Pharmacies

4. Market Trends and Forecast Analysis by Region from 2019 to 2031

• 4.1: Global Carbapenem-Based Antibiotic Market by Region
• 4.2: North American Carbapenem-Based Antibiotic Market
  • 4.2.1: North American Market by Type: Meropenem, Imipenem, Doripenem, Tebipenem, and Others
  • 4.2.2: North American Market by Distribution Channel: Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies
• 4.3: European Carbapenem-Based Antibiotic Market
  • 4.3.1: European Market by Type: Meropenem, Imipenem, Doripenem, Tebipenem, and Others
  • 4.3.2: European Market by Distribution Channel: Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies
• 4.4: APAC Carbapenem-Based Antibiotic Market
  • 4.4.1: APAC Market by Type: Meropenem, Imipenem, Doripenem, Tebipenem, and Others
  • 4.4.2: APAC Market by Distribution Channel: Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies
• 4.5: ROW Carbapenem-Based Antibiotic Market
  • 4.5.1: ROW Market by Type: Meropenem, Imipenem, Doripenem, Tebipenem, and Others
  • 4.5.2: ROW Market by Distribution Channel: Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies

5. Competitor Analysis

• 5.1: Product Portfolio Analysis
• 5.2: Operational Integration
• 5.3: Porter's Five Forces Analysis

6. Growth Opportunities and Strategic Analysis

• 6.1: Growth Opportunity Analysis
  • 6.1.1: Growth Opportunities for the Global Carbapenem-Based Antibiotic Market by Type
  • 6.1.2: Growth Opportunities for the Global Carbapenem-Based Antibiotic Market by Indication
  • 6.1.3: Growth Opportunities for the Global Carbapenem-Based Antibiotic Market by Distribution Channel
  • 6.1.4: Growth Opportunities for the Global Carbapenem-Based Antibiotic Market by Region
• 6.2: Emerging Trends in the Global Carbapenem-Based Antibiotic Market
• 6.3: Strategic Analysis
  • 6.3.1: New Product Development
  • 6.3.2: Capacity Expansion of the Global Carbapenem-Based Antibiotic Market
  • 6.3.3: Mergers, Acquisitions, and Joint Ventures in the Global Carbapenem-Based Antibiotic Market
  • 6.3.4: Certification and Licensing

7. Company Profiles of Leading Players

• 7.1: Pfizer
• 7.2: Merck
• 7.3: Saint-Gobain
• 7.4: Fresenius Kabi
• 7.5: GlaxoSmithKline
• 7.6: Eli Lilly and Company
• 7.7: Teva Pharmaceutical Industries
• 7.8: AstraZeneca
• 7.9: Meiji Holdings
• 7.10: Sandoz International